Key Points
- To evaluate the role of endomyocardial biopsy in establishing an etiological diagnosis and guiding clinical management in patients presenting with high-risk fulminant myocarditis complicated by cardiogenic shock.
- Evaluated 3 consecutive patients with high-risk myocarditis who developed cardiogenic shock and were admitted to the cardiac intensive care unit between 2024 and 2025.
- Conducted endomyocardial biopsy with histopathological examination and reverse transcriptase polymerase chain reaction (PCR) testing of cardiac tissue alongside non-invasive cardiac magnetic resonance imaging and echocardiography.
- Tissue PCR detected parvovirus B19 DNA directly in myocardium in 2 patients despite negative plasma and blood PCR results, directing standard heart failure therapy and avoidance of unnecessary immunosuppression.
- Biopsy confirmed extensive lymphocytic inflammation and latent cytomegalovirus in 1 patient with morbid obesity and human immunodeficiency virus, supporting the continuation of methylprednisolone boluses and immunoglobulin supplementation.
- Following etiology-guided therapy, all 3 patients achieved clinical stabilization and recovery of left ventricular ejection fraction, which improved from nadirs of 11%–17% to 37%–60% during follow-up.
Endomyocardial biopsy is a crucial diagnostic tool in fulminant myocarditis that can identify specific viral or inflammatory etiologies and guide targeted therapies.